Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 204 participants.

Also called NCT07800572

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 204 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07800572
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07800572. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-06 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)
Condition
Acute Ischemic Stroke
Intervention (Drug)
Anisodine Hydrobromide
Intervention (Drug)
Anisodine Hydrobromide Placebo
Lead sponsor
Capital Medical University (class: other)

Record details

Record id
cardio:ct-nct07800572
Content hash
f0c31db81ec4a9e173a4413aa33c18b12518a71bce1358f60bfc98c3a525e83f